CSL112: Phase IIb started

CSL began the double-blind, placebo-controlled, dose-escalation, international Phase IIb AEGIS-I trial to evaluate 2 dose levels of once-weekly IV CSL112 for 4 weeks in 1,200 patients who experienced ...